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Summary. Background: Heparin-induced thrombocytopenia (HIT) is a life-threatening drug reaction caused by antiplatelet factor 4/heparin (anti-PF4/H) antibodies. Commercial tests to detect these antibodies have suboptimal operating characteristics. We previously developed a diagnostic algorithm for HIT that incorporated 'four Ts' (4Ts) scoring and a stratified interpretation of an anti-PF4/H enzyme-linked immunosorbent assay (ELISA) and yielded a discriminant accuracy of 0.97 (95% confidence interval [CI] , 0.93-1.00). Objectives: The purpose of this study was to validate the algorithm in an independent patient population and quantitate effects that algorithm adherence could have on clinical care. Methods: A retrospective cohort comprised patients who had undergone anti-PF4/H ELISA and serotonin release assay (SRA) testing in our healthcare system from 2010 to 2014. We determined the algorithm recommendation for each patient, compared recommendations with the clinical care received, and enumerated consequences of discrepancies. Operating characteristics were calculated for algorithm recommendations using SRA as the reference standard. Results: Analysis was performed on 181 patients, 10 of whom were ruled in for HIT. The algorithm accurately stratified 98% of patients (95% CI, 95-99%), ruling out HIT in 158, ruling in HIT in 10 and recommending an SRA in 13 patients. Algorithm adherence would have obviated 165 SRAs and prevented 30 courses of unnecessary antithrombotic therapy for HIT. Diagnostic sensitivity was 0.82 (95% CI, 0.48-0.98), specificity 0.99 (95% CI, 0.97-1.00), PPV 0.90 (95% CI, 0.56-0.99) and NPV 0.99 (95% CI, 0.96-1.00). Conclusions: An algorithm incorporating 4Ts scoring and a stratified interpretation of the anti-PF4/H ELISA has good operating characteristics and the potential to improve management of suspected HIT patients.
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Background
Heparin-induced thrombocytopenia (HIT) is a clinicalpathological diagnosis requiring demonstration of pathogenic antiplatelet factor 4/heparin (anti-PF4/H) antibodies in a patient whose platelet count falls in specific temporal relationship to an immunizing exposure to heparin [1, 2] . Thrombotic complications (including deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction and limb ischemia/gangrene) occur in up 50% of patients with HIT; therefore rapid, accurate diagnosis is essential [2] . Multiple PF4-dependent immunoassays and platelet activation assays are available to detect HIT-related antibodies, but these have variable availability and operating characteristics [1, [3] [4] [5] . Over-diagnosis of HIT is common, often because of misinterpretation of widely available but poorly specific immunoassays ordered for patients with low clinical pretest probability of HIT [6] [7] [8] . Diagnostic errors can lead to life-threatening hemorrhagic and thrombotic complications [8] [9] [10] . We and others have investigated combining the results of a clinical score with an immunoassay to improve diagnostic accuracy for HIT in order to improve patient outcomes [3, [11] [12] [13] [14] .
In a previous study, we developed a Bayesian approach to the diagnostic evaluation and management of HIT using the 'four Ts' (4Ts) score and a stratified interpretation of the anti-PF4/H enzyme-linked immunosorbent assay (ELISA) [11] . This approach yielded a discriminant accuracy of 0.97 (95% confidence interval [CI], 0.93-1.00) for diagnosis of HIT. An algorithm was developed so that clinicians could explicitly apply Bayesian reasoning at the bedside without the necessity for performing Bayesian calculations. Clinicians could simply use the algorithm (Table 1) to translate a 4Ts score and anti-PF4/H ELISA result into a post-test probability of HIT with an associated recommendation to guide clinical action.
Our hypothesis was that clinical implementation of this algorithm could reduce over-diagnosis of HIT, preventing patients from undergoing unnecessary serotonin release assay (SRA) testing and presumptive antithrombotic therapy for HIT pending SRA results. This study had two specific aims: (i) to calculate the operating characteristics of the algorithm in an independent patient population tested at an independent coagulation laboratory; and (ii) to quantitate beneficial and detrimental effects that algorithm adherence would potentially have had on clinical care.
Methods
This study was approved by Banner Health Institutional Review Board. We retrospectively identified consecutive patients for whom serum was submitted to the coagulation laboratory at Banner -University Medical Center Phoenix for anti-PF4/H ELISA and SRA testing between September 2010 and March 2014. This constituted a retrospective cohort of inpatients from Banner Medical Centers in the Phoenix metropolitan area referred through Quest Diagnostics Ò Laboratory, San
Juan Capistrano, CA, USA. A sample size of 200 patients was calculated to provide 95% CIs of AE 15% for calculation of sensitivity and PPV and AE 5% for specificity and NPV assuming a 12% incidence of HIT in our study population [11] . We retrospectively abstracted data from each patient's medical record. Patients were excluded from further analysis if the SRA result was indeterminate or there was insufficient documentation to calculate a 4Ts score or to establish the proper temporal relationship between heparin administration and HIT diagnostic testing.
The 4Ts score was determined by two independent clinician researchers blinded to the SRA results, with adjudication by a third physician researcher in the case of discrepancy. Clinical outcomes were abstracted including significant bleeding complications (those requiring transfusion or intracranial bleeding) and thrombotic complications including venous thromboembolism, stroke and acute myocardial infarction.
Our coagulation laboratory uses a polyspecific (detecting IgG, IgM and IgA) anti-PF4/H ELISA assay (PF4 Enhanced Ò Immucor, GTI Diagnostics Inc., Waukesha, WI, USA) and refers SRA testing to Quest Diagnostics Ò .
The SRA performed by Quest Diagnostics Ò utilizes washed platelets from two separate donors, either women without a history of pregnancy or men. Testing is performed in 96-well plates and includes a weak positive control serum. This assay is externally validated via samples sent to two different laboratories (Chantilly, VA, USA and Hamilton, ON, Canada). The diagnosis of HIT was determined by an SRA with ≥ 50% release at low heparin concentration (0.1 and/or 0.5 IU mL
À1
) and a reduction of release by at least 50% at high heparin HIT ruled in 0.600-1.499 54% Order SRA* < 0.600 0 HIT ruled out/ Order SRA*** anti-PF4/H, anti-platelet factor 4/heparin; ELISA, enzyme-linked immunosorbent assay; HIT, heparin-induced thrombocytopenia; SRA, serotonin release assay; OD, optical density. We suggest that the final recommendation in this algorithm should be modified to 'Order SRA' (see Discussion). *Stop heparin and start alternative antithrombotic therapy for HIT pending SRA results. †No need for SRA. ‡Stop heparin, begin treatment, no need for SRA. *** Original algorithm recommendation: HIT ruled in, modified algorithm recommendation: Order SRA (see discussion).
concentration (100 IU mL
). The 50% serotonin-release threshold for a positive SRA, which has been used in recent studies of HIT [13, 15] , is based on HIT working group recommendations [16] , as it optimizes specificity of a diagnosis of HIT with minimal loss of sensitivity.
We calculated the incidence of HIT in each of the three clinical risk categories defined by the 4Ts score and in each of the three algorithm recommendation categories corresponding to each patient's 4Ts score and anti-PF4/H ELISA result (as delineated in Table 1 ). These three categories were: (i) 'HIT ruled in, Stop heparin, begin treatment, no need for SRA; (ii) 'HIT ruled out', No need for SRA; and (iii) 'Order SRA', Stop heparin and start alternative antithrombotic therapy for HIT, pending SRA results. We calculated the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of patients who were either ruled out or ruled in for HIT according to the algorithm. Patients for whom the algorithm recommended 'Order SRA' were excluded from calculations of diagnostic operating characteristics because this an indeterminate diagnostic result. Overall accuracy was defined as the number of patients for whom algorithm recommendations were correct divided by the total number of patients.
The potential clinical effects of algorithm adherence were determined by analysis of cases in which clinicians' management of HIT was discrepant from algorithm recommendations. Discrepant algorithm recommendations were classified as potentially beneficial or detrimental, depending on whether they were ultimately proven correct once the diagnosis of HIT was established. For instance, if the algorithm recommendation was 'HIT ruled out,' then algorithm adherence would have been potentially beneficial for a patient who subsequently ruled out for HIT by preventing unnecessary SRA testing and presumptive antithrombotic therapy for HIT. The same recommendation would have been potentially detrimental if the patient subsequently ruled in, because recommendation adherence would have missed the diagnosis of HIT. All cases in which adherence to algorithm recommendations would have been potentially detrimental (false positives and false negatives) were reviewed in detail. The results of potential clinical implementation were evaluated to determine if the algorithm should be modified to improve the potential impact on clinical care.
Results
Two hundred and nineteen patients underwent combined anti-PF4/H ELISA and SRA testing in our laboratory and reference laboratory, respectively, between September 2010 and March 2014. Twenty-three patients were excluded because of insufficient documentation to calculate a 4Ts score, 12 were excluded because of lack of documentation to establish the proper temporal relationship between heparin administration and diagnostic testing, and three because of indeterminate SRA results.
Analysis was performed on the remaining 181 patients. HIT was diagnosed in 11 (6%) patients, all of whom had intermediate or high pretest probability of HIT based on 4Ts score. Five patients experienced deep vein thrombosis (DVT) as a complication of HIT, and four of these also experienced pulmonary embolism (PE). Four patients without HIT developed a DVT, and one experienced a PE. Calculated 4Ts scores (AP, TW, RR) revealed 93 of the 181 patients (51%) had a low-risk 4Ts score (≤ 3 points), 79 (44%) had an intermediate-risk score (4-5 points) and nine (5%) a high-risk score (≥ 6 points). The incidence of HIT in each of these groups was 0/93 (95% CI, 0.0-0.4%), 7/79 (8.9%; 95% CI, 4.4-17.2%) and 3/9 (33.3%; 95% CI, 12.1-64.6%), respectively.
The algorithm accurately stratified 178/181 (98%; 95% CI, 95-99) subjects, recommending 'HIT ruled out' in 158, 'Order SRA' in 13 and 'HIT ruled in' in 10. Excluding the non-diagnostic 'Order SRA' category, sensitivity was 82% (95% CI, 48-98%), specificity 99% (95% CI, 97-100%), PPV 90% (95% CI, 56-99%) and NPV 99% (95% CI, 96-100%) ( Table 2) .
Algorithm adherence would have prevented 165 unnecessary SRA tests ordered by clinicians and prevented 30 patients from receiving unnecessary presumptive antithrombotic therapy for HIT, two of whom experienced significant bleeding complications. Algorithm adherence would also have correctly provided presumptive antithrombotic therapy for HIT to two patients who did not receive it and who were ultimately diagnosed with HIT by a positive SRA. Neither of these patients experienced thrombotic complications, despite the delay in treatment initiation.
However, algorithm adherence would have been potentially detrimental in the care of three patients. Two HIT, heparin-induced thrombocytopenia; NPV, negative predictive value; PPV, positive predictive value; SRA, serotonin release assay (SRA). *Recommendations of 'Order SRA' excluded from operating characteristic calculations because of the recommendation being non-diagnostic. patients had false-negative algorithm recommendations (a recommendation of 'HIT ruled out' in a patient who was subsequently ruled in for HIT by SRA) and one had a false-positive algorithm recommendation ('HIT ruled in' in a patient who was subsequently ruled out for HIT by SRA).
The patient representing the first false-negative case was admitted for massive pulmonary embolism and developed thrombocytopenia 2 days after initiation of a heparin infusion. She had a 4Ts score of 4, an anti-PF4/H ELISA of 0.537 OD (optical density) and an algorithm recommendation of 'HIT ruled out'. The clinician initially decided to order an SRA and start argatroban, but later (correctly) determined that the ELISA result was unlikely to support a diagnosis of HIT in this clinical setting. He subsequently stopped argatroban and started therapeutic dose enoxaparin, continuing it despite a positive SRA result reported several days later. Recovery of thrombocytopenia despite ongoing enoxaparin therapy indicated that the SRA result in this case was a false-positive. Although this algorithm recommendation was included as a false-negative in our statistical analysis below, it was reclassified as a true-negative after this adjudication (see Discussion).
The patient representing the second false-negative case developed thrombocytopenia 9 days after receiving heparin during coronary artery bypass surgery. He had a 4Ts score of 6, anti-PF4/H ELISA 0.573 OD and an algorithm recommendation of 'HIT ruled out'. However, his SRA was strongly positive and his thrombocytopenia recovered upon treatment with fondaparinux. The falsenegative algorithm recommendation in this case was, therefore, confirmed to be false-negative.
The patient representing the false-positive case was admitted for orthotopic liver transplantation and developed thrombocytopenia and a postoperative DVT 15 days after first receiving heparin packing in a dialysis catheter. He had a 4Ts score of 6, an anti-PF4/H ELISA 1.725 OD and an algorithm recommendation 'HIT ruled in'. His SRA was negative and he received heparin again 8 days later without clinical manifestations of HIT. The false-positive algorithm recommendation in this case was, therefore, confirmed to be a false-positive.
Discussion
Our original algorithm was derived using data obtained from patients tested in Hamilton, Ontario, Canada, in 2006-2007 [11] and demonstrated reasonable operating and clinical characteristics in a population of patients tested in Phoenix, Arizona, in 2010-2014. Our observations suggest that implementation of our algorithm could reduce inefficient use of the SRA and unnecessary presumptive antithrombotics for HIT, thereby potentially reducing associated bleeding complications and cost.
Algorithm recommendations were considered erroneous in three patients in our initial analysis, but upon adjudication, one false-negative recommendation was reclassified as true-negative. The other observed false-negative recommendation could have been avoided if we had recommended SRA testing for patients with a high-risk 4Ts score and an anti-PF4/H ELISA result < 0.6 OD. This modification of our algorithm is supported by data showing that the risk of HIT is 16% (95% CI, 4-62%) in patients with a high-risk 4Ts score and a negative immunoassay result [14] and is consistent with the diagnostic approach recommended by Linkins and Leroux [13, 17] . We therefore recommend that patients with a high-risk 4Ts score and low anti-PF4/H ELISA OD (< 0.6) undergo SRA testing. This modification to our algorithm would have required four additional SRAs in our cohort of 181 patients and, combined with adjudication, would have improved the sensitivity and NPV of our algorithm to 100% (see Tables 3 and 4) .
A Bayesian approach using the 4Ts scores and anti-PF4/H ELISA may help guide clinical decision making [3, 11] . Because of variation in study design and differences in sensitivities and specificities of different immunoassays [18] , it is difficult to make direct comparisons between our study and others in which the 4Ts score and various HIT immunoassays were used together to make the diagnosis of HIT. We were unable to find previous studies with comparative data that employed a stratified interpretation of the anti-PF4/H immunoassay. However, three previous studies provided data sufficient to calculate operating characteristics of a diagnostic strategy incorporating the 4Ts score with an anti-PF4/H immunoassay and using the SRA as the reference standard [13, 14, 19] . Table 4 shows a comparison of operating characteristics between these studies and ours. Our study has several limitations. Our study sample was small and does not necessarily represent the overall population of patients tested for HIT, because in clinical practice some patients are diagnosed and treated without ordering an SRA. Additionally, there was a lower than expected number of HIT patients (6.1%) in our sample, resulting in a large confidence interval for the calculation of sensitivity. Although the 4Ts score has been widely validated, inter-rater reliability as measured by the kappa statistic has ranged from 0.36 to 0.84 [13, 20, 21] . Our algorithm performance is contingent on a reliable 4Ts score. The anti-PF4/H immunoassay used in our study is shared by 62% of US hospitals participating in a recent College of American Pathologists (CAP) survey [22] , but other immunoassays are commercially available, and the OD cut-offs used in our algorithm may not be universally generalizable [23] . Facilities interested in using our algorithm should enlist the participation of their local coagulation laboratory to determine whether their immunoassay is reasonably compatible with that used in our study.
We employed a proxy diagnosis for HIT, based only on the SRA, so that the reference standard for diagnosis in our study would be independent from the diagnostic variables used in our algorithm. In clinical practice, however, the diagnosis of HIT should not be based on the SRA alone. Our algorithm provides a clinical-pathologic approach to the diagnosis of HIT that primarily employs 4Ts scoring and the anti-PF4/H ELISA, but utilizes the SRA in cases in which it is most needed to confirm the diagnosis. The possibility of a false-positive SRA should be carefully considered in instances when the SRA is positive in the face of a negative immunoassay, as recommended in a recent review article on the SRA [24] . A published algorithm can be used to resolve the diagnosis of HIT in patients with indeterminate SRA results [25] .
Our algorithm was designed to help clinicians take advantage of a sophisticated statistical approach to interpretation of the anti-PF4/H ELISA in a way that is relatively easy to use at the bedside. We recommend making a simple modification to reduce the risk of false-negative algorithm recommendations by ordering an SRA in all patients with a high risk 4Ts score, regardless of negative immunoassay results, This modification is consistent with previous recommendations of other authors [13, 14] . The favorable operating characteristics of our algorithm in two geographically and temporally independent patient populations support its generalizability. We have proposed that our coagulation laboratory provide the algorithm and a 4Ts score table when reporting a quantitative anti-PF4/H ELISA result to clinicians. We are currently developing logic within our electronic medical record that will incorporate the algorithm into a clinical decision support system designed to help clinicians recognize, diagnose and manage HIT accurately and efficiently. No algorithm should supplant thoughtful bedside decision making.
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